Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. HOOD
10. IBM

Go back to Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update

Intra-Cellular Therapies (ITCI) Tops Q4 EPS by 7c

March 2, 2020 7:31 AM EST

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.74), $0.07 better than the analyst estimate of ($0.81).

We are very excited about the recent FDA approval of CAPLYTA (lumateperone) for the treatment of schizophrenia and we are fully prepared for our planned commercial launch later this... More